Kajohnsak Noppakun

Prof. Kajohnsak Noppakun

Chiang Mai University, Chiang Mai, Thailand
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Kidney International
Verified
Journal Article
Closed access
BRBrad H. Rovin
Brad H. Rovin
NSNeil Solomons
Neil Solomons
MDMary Anne Dooley
Mary Anne Dooley
JTJames Tumlin
James Tumlin
LLLidia Lysenko
Lidia Lysenko
KNKajohnsak Noppakun
Kajohnsak Noppakun

1 February 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
SNSurapon Nochaiwong
Surapon Nochaiwong
CRChidchanok Ruengorn
Chidchanok Ruengorn
RARatanaporn Awiphan
Ratanaporn Awiphan
KKKiatkriangkrai Koyratkoson
Kiatkriangkrai Koyratkoson
CCChayutthaphong Chaisai
Chayutthaphong Chaisai
KTKednapa Thavorn
Kednapa Thavorn
Existing epidemiological studies illustrate that proton pump inhibitors (PPIs) may be related to adverse kidney outcomes. To date, no comprehensive meta-analysis has been conducted to evaluate and quantify this association. We performed a systematic review and meta-analysis of studies to assess the association between PPI use and the risk of adverse kidney outcomes. We searched MEDLINE, Embase, SCOPUS, Web of Science, CINAHL, Cochrane Library and grey literature with no language restrictions (through 31 October 2016). Adverse kidney outcomes were acute interstitial nephritis (AIN), acute kidney injury (AKI), chronic kidney disease (CKD) and end-stage renal disease (ESRD). The risk ratios (RRs) and confidence intervals (CIs) were pooled using a random effects model. The strength of evidence (SOE) for each outcome was assessed using the Grading of Recommended Assessment, Development and Evaluation system. Of 2037 identified studies, four cohort and five case–control studies with ∼2.6 million patients were included. Of these, 534 003 (20.2%) were PPI users. Compared with non-PPI users, PPI users experienced a significantly higher risk of AKI [RR 1.44 (95% CI 1.08–1.91); P = 0.013; SOE, low] and CKD [RR 1.36 (95% CI 1.07–1.72); P = 0.012; SOE, low]. Moreover, PPIs increased the risk of AIN [RR 3.61 (95% CI 2.37–5.51); P < 0.001; SOE, insufficient] and ESRD [RR 1.42 (95% CI 1.28–1.58); P < 0.001; SOE, insufficient]. PPI usage was associated with adverse kidney outcomes; however, these findings were based on observational studies and low-quality evidence. Additional rigorous studies are needed for further clarification.

12 May 2011 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KNKajohnsak Noppakun
Kajohnsak Noppakun
FCF. G. Cosio
F. G. Cosio
PDP. G. Dean
P. G. Dean
STS. J. Taler
S. J. Taler
RWR. Wauters
R. Wauters
JGJ. P. Grande
J. P. Grande
We assessed the relationship between living donor (LD) age and kidney survival in 1063 adults transplanted between 1980 and 2007. Increasing LD age was associated with lower kidney function (GFR) before and after transplantation and loss of GFR beyond 1 year. Increasing LD age was also associated with low-moderate proteinuria posttransplant (151–1500 mg/day, p < 0.0001). By univariate analysis, reduced graft survival related to lower GFR at 1 year [HR = 0.925 (0.906–0.944), p < 0.0001], proteinuria [HR = 1.481 (1.333–1.646), p < 0.0001] and increasing LD age [HR = 1.271 (1.219–1.326), p = 0.001]. The impact of LD age on graft survival was noted particularly >4 years posttransplant and was modified by recipient age. Thus, compared to a kidney graft that was within 5 years of the recipient age, younger kidneys had a survival advantage [HR = 0.600 (0.380–0.949), p = 0.029] while older kidneys had a survival disadvantage [HR = 2.217 (1.507–3.261), p < 0.0001]. However, this effect was seen only in recipients <50 years old. By multivariate analysis, the relationship between LD age and graft survival was independent of GFR but related to proteinuria. In conclusion, LD age is an important determinant of long-term graft survival, particularly in younger recipients. Older kidneys with reduced survival are identifiable by the development of proteinuria posttransplant.

1 August 2020 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
Pajaree KrisanapanPajaree Krisanapan
Pajaree Krisanapan
SVSurachet Vongsanim
Surachet Vongsanim
PPPathomporn Pin-On
Pathomporn Pin-On
CRChidchanok Ruengorn
Chidchanok Ruengorn
KNKajohnsak Noppakun
Kajohnsak Noppakun

4 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SNSurapon Nochaiwong
Surapon Nochaiwong
CRChidchanok Ruengorn
Chidchanok Ruengorn
KKKiatkriangkrai Koyratkoson
Kiatkriangkrai Koyratkoson
KTKednapa Thavorn
Kednapa Thavorn
RARatanaporn Awiphan
Ratanaporn Awiphan
TIThai Renal Outcomes Research (THOR) Investigators
Thai Renal Outcomes Research (THOR) Investigators
A tool to predict peritonitis-associated treatment failure among peritoneal dialysis (PD) patients has not yet been established. We conducted a multicentre, retrospective cohort study among 1,025 PD patients between 2006 and 2016 in Thailand to develop and internally validate such a tool. Treatment failure was defined as either a requirement for catheter removal, a switch to haemodialysis, or peritonitis-associated mortality. Prediction model performances were analysed using discrimination (C-statistics) and calibration (Hosmer-Lemeshow test) tests. Predictors were weighted to calculate a risk score. In total, 435 patients with 855 episodes of peritonitis were identified; 215 (25.2%) episodes resulted in treatment failure. A total risk score of 11.5 was developed including, diabetes, systolic blood pressure 1,000/mm3 and >100/mm3 on days 3–4 and day 5, respectively. The discrimination (C-statistic = 0.92; 95%CI, 0.89–0.94) and calibration (P > 0.05) indicated an excellent performance. No significant difference was observed in the internal validation cohort. The rate of treatment failure in the different groups was 3.0% (low-risk, 9 points). A simplified risk-scoring scheme to predict treatment failure may be useful for clinical decision making regarding PD patients with peritonitis. External validation studies are needed.

16 June 2016 in Open Heart
Verified
Journal Article
Open access
PDF file
SNSurapon Nochaiwong
Surapon Nochaiwong
CRChidchanok Ruengorn
Chidchanok Ruengorn
RARattanaporn Awiphan
Rattanaporn Awiphan
PDPhongsak Dandecha
Phongsak Dandecha
KNKajohnsak Noppakun
Kajohnsak Noppakun
APArintaya Phrommintikul
Arintaya Phrommintikul
Objective To systematically review and meta-analyse the risk–benefit ratio of warfarin users compared with non-warfarin users in patients with atrial fibrillation (AF), who are undergoing dialysis. Methods We searched PubMed/MEDLINE, EMBASE, SCOPUS, Web of Science, Cochrane Library, grey literature, conference proceedings, trial registrations and also did handsearch. Cohort studies without language restrictions were included. Two investigators independently conducted a full abstraction of data, risk of bias and graded evidence. Effect estimates were pooled using random-effect models. Main outcome measure All-cause mortality, total stroke/thromboembolism and bleeding complications. Results 14 studies included 37 349 dialysis patients with AF, of whom 12 529 (33.5%) were warfarin users. For all-cause mortality: adjusted HR=0.99 (95% CI 0.89 to 1.10; p=0.825), unadjusted risk ratio (RR)=1.00 (95% CI 0.96 to 1.04; p=0.847). For stroke/thromboembolism: adjusted HR=1.06 (95% CI 0.82 to 1.36; p=0.676), unadjusted incidence rate ratio (IRR)=1.23 (95% CI 0.94 to 1.61; p=0.133). For ischaemic stroke/transient ischaemic attack, adjusted HR=0.91 (95% CI 0.57 to 1.45; p=0.698), unadjusted IRR=1.16 (95% CI 0.84 to 1.62; p=0.370). For haemorrhagic stroke, adjusted HR=1.60 (95% CI 0.91 to 2.81; p=0.100), unadjusted IRR=1.48 (95% CI 0.92 to 2.36; p=0.102). Major bleeding was increased among warfarin users; adjusted HR=1.35 (95% CI 1.11 to 1.64; p=0.003) and unadjusted IRR=1.22 (95% CI 1.07 to 1.40; p=0.003). Conclusions Among dialysis patients with AF, warfarin therapy was not associated with mortality and stroke/thromboembolism, but significantly increased the risk of major bleeding. More rigorous studies are essential to demonstrate the effect of warfarin for stroke prophylaxis in dialysis patients with AF.